Searching the Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
It is known that the symptoms of Parkinson's disease (PD) progress successively, early and accurate diagnosis of the disease is of great importance, which slows the disease deterioration further and alleviates mental and physical suffering. In this paper, we propose a joint regression and classification scheme for PD diagnosis using baseline multi-modal neuroimaging data. Specifically, we devise a new feature selection method via relational learning in a unified multi-task feature selection model. Three kinds of relationships (e.g., relationships among features, responses, and subjects) are integrated to represent the similarities among features, responses, and subjects. Our proposed method exploits five regression variables (depression, sleep, olfaction, cognition scores and a clinical label) to jointly select the most discriminative features for clinical scores prediction and class label identification. Extensive experiments are conducted to demonstrate the effectiveness of the proposed method on the Parkinson's Progression Markers Initiative (PPMI) dataset. Our experimental results demonstrate that multi-modal data can effectively enhance the performance in class label identification compared with single modal data. Our proposed method can greatly improve the performance in clinical scores prediction and outperforms the state-of-art methods as well. The identified brain regions can be recognized for further medical analysis and diagnosis.
Pubmed ID: 29689760
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
An observational longitudinal clinical study partnership to identify and validate biomarkers of Parkinson disease (PD) progression and provide easy and open web-based access to the comprehensive set of correlated clinical data and biospecimens, information, and biosamples acquired from PD and age and gender matched healthy control subjects to the research community. The data and specimens have been collected in a standardized manner under strict protocols and includes clinical (demographic, motor and non-motor, cognitive and neurobehavioral), imaging (raw and processed MRI, SPECT and DAT), and blood chemistry and hematology subject assessments and biospecimen inventories (serum, plasma, whole blood, CSF, DNA, RNA and urine). All data are de-identified to protect patient privacy. PPMI will be carried out over five years at 21 clinical sites in the United States and Europe and requires the participation of 400 Parkinson's patients and 200 control participants. The PPMI database provides researchers with access to correlated clinical and imaging data, along with annotated biospecimens, all available within an open access system that encourages data sharing (http://www.ppmi-info.org/access-data-specimens/). The website hosts an Ongoing Analysis section to keep the scientific community apprised of analyses being completed, in hopes of stimulating collaborations between researchers who are using PPMI data and specimens.
View all literature mentionsSoftware package for analysis of brain imaging data sequences. Sequences can be a series of images from different cohorts, or time-series from same subject. Current release is designed for analysis of fMRI, PET, SPECT, EEG and MEG.
View all literature mentions